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Improving catalyst activity in secondary amine 
catalysed transformations 
John B. Brazier,a Timothy J. K. Gibbs,a Julian H. Rowley,b Leopold Samulis,a 
Sze Chak Yau,a Alan R. Kennedy, James A. Plattsa and 
Nicholas C. O. Tomkinsonb,* 
The effect on catalyst performance of altering substituents at the 2-position of the Macmillan 
imidazolidinone has been examined. Condensation of L-phenylalanine N-methyl amide with 
acetophenone derivatives results in a series of imidazolidinones whose salts can be used to 
accelerate the Diels-Alder cycloaddition. Electron withdrawing groups significantly increases 
the overall rate of cycloaddition without compromise in selectivity. The most effective catalyst 
was shown to be efficient for a variety of substrates and the applicability of this catalyst to 
alternative secondary amine catalysed transformations is also discussed. 
 
Introduction 
Catalyst design generally relies upon serendipity and extensive 
high throughput screening which has frequently proved to be 
effective in asymmetric synthesis. However, pressure to reduce 
financial and environmental footprints provides inspiration for 
innovation. The use of predictive models represents the future 
of asymmetric synthesis whereby bespoke catalysts can be 
tailored to specific reactions with minimal laboratory screening. 
Current models, however, frequently fall short of the accuracy 
required to be effective predictors of both activity and 
selectivity.1 An alternative approach is to draw inspiration from 
mechanistic knowledge where a combination of kinetic 
experiment and intelligent design allows interrogation, 
reinforcing and underpinning of hypotheses.2 
 Amine catalysis represents an important area of 
contemporary synthetic chemistry. Since their introduction the 
fields of LUMO, HOMO and SOMO catalysis have been 
established as the most significant areas of Organocatalysis.3  
This is due, in part, to the wide variety of reactions which have 
been developed using secondary amines along with the 
excellent yields and outstanding levels of selectivity which are 
commonly achieved in these transformations.4,5 The field also 
follows some of the principles of Green chemistry which has 
further enhanced applicability, particularly in the industrial 
environment. Reducing levels of catalyst loading necessary to 
bring about reaction at an effective rate would further increase 
this potential.6 
 Within the field of LUMO catalysis using secondary amines 
a consistent mechanism has been accepted, the fundamental 
steps of which are outlined in Figure 1.7,8,9 In Step 1 the 
secondary amine salt 1 condenses ZLWK WKH Įȕ-unsaturated 
carbonyl compound 2 to form the reactive iminium ion 3. In 
Step 2 the diene 4 undergoes cycloaddition with the activated 
ʌ-system of 3 to form the iminium ion of the product 5. Finally, 
in Step 3 the iminium ion 5 undergoes hydrolysis/solvolysis to 
release the product (e.g. acetal 6) and regenerate the secondary 
amine salt 1.10 
 
Figure 1. Catalytic cycle for imidazolidinone catalysed Diels-
Alder cycloaddition. 
 
 For the Diels-Alder cycloaddition reaction, under literature 
optimised conditions, it has been shown the rate determining 
step of the catalytic cycle is iminium ion formation (Step 1).11 
Iminium ion formation consists of a number of mechanistic 
steps, whereby distinct equilibria require the amine to have 
different properties.12 Figure 2 shows a series of productive 
equilibria from Step 1 leading to a reactive iminium ion 12. 
Reduced basicity of the amine 7 drives Equilibrium 1 and 
Equilibrium 4 in the forward direction whereas amine 
nucleophilicity is required for Equilibrium 3 to proceed 
forwards. It is well established that the basicity of an amine is 
intimately linked to its nucleophilicity, therefore, positively 
influencing Equilibrium 1 and Equilibrium 4 by reducing 
basicity can negatively impact Equilibrium 3 by reducing 
  
  
nucleophilicity. Therefore in order to influence Step 1 of the 
catalytic cycle the electronics of the amine must be balanced 
through appropriate substitution. 
 
Figure 2. Considerations within Step 1 of the catalytic cycle. 
 
 Within the literature there are two principal catalyst 
scaffolds developed for accelerating the Diels-Alder reaction 
through iminium ion intermediates (Figure 3): The 
imidazolidinones13 and the diarylprolinol ethers;14 the 
imidazolidinones having a higher level of activity in this 
reaction.15 We therefore elected to examine the imidazolidinone 
architecture to discover catalysts with higher levels of 
activity.16,17 Within this manuscript we prepare a series of 
imidazolidinone structures based upon our mechanistic 
understanding of the reaction and explore the reactivity of these 
catalysts. 
 
Figure 3. Imidazolidinone and diarylprolinol ether catalysts. 
 
 Understanding how substituents on the secondary amine can 
affect basicity, nucleophilicity, and hence the rate of Step 1 was 
deemed crucial for influencing reactivity. Modelling studies 
had previously shown the highest activation barrier within 
iminium ion formation was Equilibrium 1 where the 
ammonium salt +; loses a proton (Figure 2).18 When 
comparing the imidazolidinone 13 and the diarylprolinol ether 
14 it was found proton affinity (PA) was a readily calculable 
theoretical measure of amine basicity to act as a predictor of 
catalyst activity.15 The benchmark imidazolidinone 13 has a PA 
of 943.1 KJ mol-1 whereas the diarylprolinol ether 14, which 
has a lower level activity, has a PA of 998.6 KJ mol-1 (Figure 
3).15 Therefore we sought to alter the basicity of 13 through 
substitution and determine influence on reactivity within a 
benchmark Diels-Alder reaction, with the expectation that 
lowering proton affinity would improve reactivity. 
 The imidazolidinone architecture 15 offers a number of 
places for developing an understanding of the relationship 
between structure and catalytic activity (Figure 4). We elected 
to examine the substituents R2 and R3 where it was thought ease 
of synthesis and proximity to the reactive nitrogen would 
engender the greatest effect on reaction outcome. 
 
Figure 4. Potential points of substitution in the imidazolidinone 
architecture. 
 
 A second fundamental requirement of the secondary amine 
catalyst is the ability to control the stereochemical outcome of 
the transformation. It was crucial for any amine with improved 
activity over 13 maintained the exceptional levels of asymmetry 
generally associated with this catalyst.7 Within the reaction of a 
secondary amine 13 and a DEunsaturated carbonyl compound 
two potential iminium ions can be formed, the E- and the Z-
isomers 16 and 17 (Scheme 1). Ratios of 16 and 17 have been 
shown to be dictated by the steric requirements of the 
substituents on the imidazolidinone ring.9 
 
Scheme 1. Origins of stereoselectivity in the imidazolidinone 
catalysed Diels-Alder cycloaddition. 
 
 For the imidazolidinone 13, following selective formation 
of the E iminium ion 17, the catalyst architecture renders 
subsequent Diels-Alder cycloaddition asymmetric, with the 
benzyl arm of the catalyst directing approach of the diene from 
the lower face of the iminium ion as shown (Scheme 1). For 
any alternative imidazolidinone structures it is essential that 
high levels of E/Z iminium control is observed to maintain 
levels of selectivity.9a 
 
Results and discussion 
Based upon the hypothesis that introduction of an electron 
withdrawing group D to the reactive nitrogen (R2 and R3 in 
15) would reduce basicity and therefore enhance reactivity a 
series of imidazolidinones 20±24 were prepared through 
condensation of phenylalanine-N-methyl amide (18) and a 
substituted acetophenone (Table 1). Reaction of 18 and 19 in 
toluene under microwave irradiation in the presence of 
ytterbium triflate gave the corresponding imidazolidinones 20±
23 with a variety of substitution on the aromatic ring.19  For 
preparation of the imidazolidinone 24, derived from 4-
nitroacetophenone, it proved necessary to develop alternative 
conditions to access the catalyst with high levels of e.e. 
Reaction of 18 with the ketone in DMF at 150 °C for 30 
minutes in the presence of methane sulfonic acid gave 24 
enantiomerically pure (Entry 6) (See Supplementary 
Information for full details of catalyst preparation). Proton 
affinity (PA) for each catalyst was calculated using Gaussian 09 
(B3LYP/6±31+G(d,p)) which showed a clear influence on 
predicted basicity of the secondary nitrogen (Entries 2±6) when 
compared to the parent structure 13 (Entry 1). Introduction of 
an aromatic ring with an electron donating substituent displayed 
a raised proton affinity (Entry 2, 970 KJ mol-1) when compared 
to 13 (Entry 1, 943 KJ mol-1). Whereas increasing the strength 
  
  
of electron withdrawing group progressively decreased the 
proton affinity of the secondary amine (Entries 3±6), with the 
lowest value being shown for imidazolidinone 24 (R = 4 
NO2C6H4, PA = 924 KJ mol-1). 
 
Table 1. Preparation of potential imidazolidinone catalysts.a 
 
 
Scheme 2. Diels-Alder cycloaddition catalysed by +&O. 
 
 The Diels-Alder cycloaddition of cinnamaldehyde and 
cyclopentadiene was used to benchmark the acetophenone 
derived catalysts 20HCl±24HCl (Scheme 2).7 Each reaction 
was performed under literature optimised reaction conditions (3 
equiv. cyclopentadiene, MeOH/H2O (19:1), 25 °C, 5 mol% 
catalyst), monitoring reaction progress by 1H NMR 
spectroscopy (See Supplementary Information for full details). 
As can be seen in Figure 5, introduction of an aromatic ring 
greatly increased the rate of the Diels-Alder cycloaddition when 
compared to the parent system 13HCl (Ƈ). This was the case 
for all acetophenone derived catalysts examined. Subtleties in 
the electronic substitution of the aromatic ring had less 
influence on the overall rate than proton affinity predictions had 
suggested (Table 1), showing a deficiency in this ground state 
prediction, however, the significantly increased reaction rate 
observed was exciting and warranted further investigation. 
 
Figure 5. Relative rates of imidazolidinone catalysed Diels-
Alder cycloaddition. 
 
 As stated previously, it was deemed essential that alongside 
an increase in reaction rate we required the high levels of 
selectivity observed with the imidazolidinone 13HCl. For each 
reaction selectivities were determined for the Diels-Alder 
adducts 26 and 27 (Table 2).20 Based upon these reaction 
outcomes we selected the imidazolidinone derived from 4-
nitroacetophenone 24 (Entry 3) for further investigations due to 
the high levels of enantioselectivity observed for both the endo 
(95% e.e.) and exo (87% e.e.) isomers of the Diels-Alder 
product. 
 
Table 2. Imidazolidinone catalysed Diels-Alder cycloaddition. 
 
 To profile the reactivity of the imidazolidinone 24 further 
we examined a series of alternative dienophiles within the 
Diels-Alder cycloaddition (Table 3). For cinnamaldehyde 
derivatives (Entries 1±4) high yields and enantioselectivities 
were maintained for both electron withdrawing and electron 
donating substituents on the aromatic ring. Reactions with 
aliphatic substituted substrates proceeded slower than reactions 
with cinnamaldehyde derivatives, however, they still 
progressed cleanly and mass balance could be accounted for 
through recovered starting material. It is believed that parasitic 
equilibria of the catalyst involving dienamine 3021 formation 
  
  
from the iminium intermediate 29 accounts for this observed 
loss in reactivity (Scheme 3). 
 
Table 3. Diels-Alder cycloaddition catalysed by +&O. 
 
Scheme 3. Parasitic dienamine formation. 
 
 Crystals of an iminium ion suitable for X-ray analysis were 
obtained through reaction of 24+3)6 and 4-
iodocinnamaldehyde (Figure 6). A low energy solid-state 
conformation of the E-iminium ion with the benzyl arm 
residing over the top of the imidazolidinone ring was observed. 
Direction of the diene to the bottom face of this iminium ion 
leads to the stereochemical outcome observed in reactions of 
24.22 Consistent with observations on the MacMillan catalyst 
13, this suggests use of 24 as a catalyst in conjugate addition 
reactions would lead to products with low levels of 
enantioselectivity,23 and increasing the steric requirement of the 
methyl group on the E-face would be necessary to prepare 
alternative catalysts to accelerate this class of reaction. 
 
Figure 6. X-Ray structure of iminium ion derived from 24 and 
4-iodocinnamaldehyde. 
 
 The importance of knowing the rate determining step of the 
catalytic cycle when altering catalyst structure is highlighted by 
examination of an alternative transformation which proceeds 
via iminium ion intermediates. For example, Mayr has shown 
that in the conjugate addition of electron rich heteroaromatics, 
such as N-methyl pyrrole 31, to an DEunsaturated carbonyl 
compound, C±C bond formation is rate determining.24  From 
this it could be expected that the 4-nitroacetophenone derived 
catalyst 24 would not significantly alter the rate of addition of 
31 to 25 (Scheme 4). 
 
Scheme 4. Conjugate addition of N-methyl pyrrole to 
cinnamaldehyde. 
 
 The addition of 31 to 25 catalysed by 13 and 24 under 
literature optimised conditions was monitored by 1H NMR 
spectroscopy (Figure 7). Each reaction proceeded smoothly to 
completion after 6 hours. As can be seen from Figure 7 each 
catalyst accelerates the reaction at a similar rate showing that 
improved activity for 24 will only be observed in 
transformations where iminium ion formation is rate 
determining. 
 
Figure 7. Comparison of the reactivity of 13 and 24 in the 
conjugate addition of N-methyl pyrrole to cinnamaldehyde. 
 
Conclusions 
In summary, we have presented a series of highly reactive 
imidazolidinone catalysts, which significantly increase the rate 
of Diels-Alder cycloaddition reactions. A low energy crystal 
structure of a proposed iminium ion intermediate suggests that 
salts of 24 induce asymmetry in a similar manner to the 
MacMillan imidazolidinone 13. The catalysts described would 
be predicted to accelerate cycloaddition reactions and conjugate 
addition reactions that proceed through a closed transition state 
and provide enhanced rates to those observed with 13 where 
iminium ion formation is the rate determining step of the 
catalytic cycle. Central to this method of catalyst design is a 
thorough understanding of reaction mechanism providing an 
attractive and practical method to improve catalyst activity. 
 
 
  
  
Experimental 
L-Phenylalanine N-methyl amide 18. L-Phenylalanine ethyl 
ester hydrochloride (30.0 g, 131 mmol) was stirred in an 
ethanolic solution of methylamine 33 wt.% (150 mL, 1.2 mol) 
for 72 hours at ambient temperature. The solvent was removed 
under reduced pressure. The resultant slurry was taken up in 
saturated sodium carbonate (50 mL) and extracted with 
chloroform (3 × 50 mL). The combined organic extracts were 
dried over anhydrous potassium carbonate and the solvent 
removed under reduced pressure to give a white solid. The 
residue was recrystallized from ethyl acetate and petroleum 
ether to give the product as white needles (17.6 g, 75%). mp: 
67±69 °C; >Į@20D   = -89.6 (c=1, CHCl3) ȣmax (film)/cm±1 3371, 
3345, 3290, 2939, 2875, 1644; 1H NMR (400 MHz, CDCl3į
7.47±7.12 (6H, m), 3.54 (1H, dd, J = 9.5, 3.9 Hz), 3.22 (1H, dd, 
J = 13.7, 3.9 Hz), 2.83 (3H, d, J = 5.0 Hz), 2.60 (1H, dd, J = 
13.7, 9.5 Hz), 1.38 (2H, s); 13C NMR (101 MHz, CDCl3 į
174.8, 138.0, 129.3, 128.7, 126.8, 56.5, 41.0, 25.8;  m/z (ES): 
179.1 (M+H+). 
 
(S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one 13. 
L-Phenylalanine-N-methyl amide (2.00 g, 11.2 mmol) was 
dissolved in acetone (10 mL) and methanol (30 mL). A small 
crystal of p-toluenesulfonic acid (<1 mg) was added and the 
mixture was heated under reflux for 18 h. The solvent was 
removed under reduced pressure and the residue taken up in 
chloroform (30 mL) and saturated sodium carbonate solution 
(30 mL). The aqueous layer was extracted with chloroform (2 × 
30 mL) and the combined organics were dried over potassium 
carbonate. The solvent was removed under reduced pressure to 
give the target compound as a pale yellow oil (2.40 g, quant.). 
>Į@20D   = -33.5 (c=1.3, MeOH) ȣmax (film)/cm±1 3473, 3329, 
3060, 3030, 2975, 2929, 1685; 1H NMR (400 MHz, CDCl3į
7.38±7.14 (5H, m), 3.82 (1H, dd, J = 6.5, 4.5 Hz), 3.17 (1H, dd, 
J = 14.2, 4.5 Hz), 3.03 (1H, dd, J = 14.2, 6.5 Hz), 2.77 (3H, s), 
1.28 (3H, s), 1.18 (3H, s); 13C NMR (126 MHz, CDCl3 į
173.7, 137.6, 129.9, 129.0, 127.2, 75.9, 59.7, 37.7, 27.6, 25.7, 
25.6; m/z (APCI): 219.2 (M+H+). 
 
General Procedure for the preparation of imidazolidinones 
20±23. A toluene solution of L-Phenylalanine-N-methyl amide 
(0.6 M), the appropriate substituted acetophenone (0.9 eq.) and 
ytterbium(III) trifluoromethanesulfonate (0.05 eq.) were heated 
under reflux for 16±69 h. The mixture was then allowed to cool 
and diethyl ether (2 vol.) was added. The solution was washed 
with 4 M potassium carbonate (0.3 vol.), water (0.3 vol.), and 
brine (0.3 vol.). The volatiles were then removed under reduced 
pressure and the desired products obtained by flash 
chromatography (ethyl acetate/heptane). 
 
(2R,5S)-5-Benzyl-2-(4-methoxyphenyl)-2,3-
dimethylimidazolidin-4-one 20. Prepared according to 
General Procedure. >Į@30D  = +36 (c 0.1, CH2Cl2); ȣmax (NaCl 
disk)/cm±1 3360, 2933, 1690, 1608, 1510; 1H NMR (500 MHz, 
CDCl3 įH 7.23±7.08 (7H, m), 6.78 (2H, d, J = 8.9 Hz), 3.81 
(1H, dd, J = 7.2 Hz, 4.2 Hz), 3.71 (3H, s), 3.08 (1H, dd, J = 13. 
9 Hz, 4.2 Hz), 2.93 (1H, dd, J = 13.9 Hz, 7.2 Hz), 2.64 (3H, s), 
1.46 (3H, s); 13C NMR (125 MHz, CDCl3 įC 173.6, 159.4, 
137.7, 134.9, 129.7, 128.5, 126.7, 126.5, 114.1, 78.4, 59.4, 
55.3, 38.4, 26.4, 26.1; LRMS m/z (ES) (M+H)+ = 311.2; HRMS 
m/z (ES) (M+H+) = 311.1753; HRMS m/z calc. (M+H+) = 
311.1760. 
 
(2R,5S)-5-Benzyl-2,3-dimethyl-2-phenylimidazolidin-4-one 
21. Prepared according to General 3URFHGXUH >Į@30D   = +3.0 (c 
0.1, CH2Cl2); ȣmax (NaCl disk)/cm±1 1693, 1454; 1H NMR (500 
MHz, CDCl3įH  7.23 (2H, t, J = 6.2 Hz), 7.20±7.09 (8H, m), 
3.76 (1H, dd, J = 7.1 Hz, 4.2 Hz), 3.05 (1H, dd, J = 13.9 Hz, 
4.2 Hz), 2.91 (1H, dd, J = 13.9 Hz, 7.1 Hz), 2.63 (3H, s), 1.45 
(3H, s); 13C NMR (125 MHz, CDCl3 įC 173.7, 142.8, 137.6, 
129.7, 128.9, 128.5, 128.1, 126.7, 125.1, 78.6, 59.3, 38.3, 26.3, 
26.2; LRMS m/z (ES) (M+H)+ = 281.2; HRMS m/z (ES) 
(M+H+) = 281.1646; HRMS m/z calc. (M+H+) = 281.1654. 
 
2R,5S)-5-Benzyl-2-(4-chlorophenyl)-2,3-
dimethylimidazolidin-4-one 22. Prepared according to 
*HQHUDO 3URFHGXUH >Į@30D   = +5.2 (c 0.1, CH3OH); ȣmax (NaCl 
disk)/cm±1 3316, 2720, 1704, 1493; 1H NMR (500 MHz, 
CDCl3 įH 7.23±7.19 (4H, m), 7.16±7.14 (3H, m), 7.13±7.09 
(2H, m), 3.76 (1H, dd, J = 6.9 Hz, 4.3 Hz), 3.06 (1H, dd, J = 
14.0 Hz, 4.3 Hz), 2.95 (1H, dd, J = 14.0 Hz, 6.9 Hz), 2.64 (3H, 
s), 1.44 (3H, s); 13C NMR (125 MHz, CDCl3įC 173.5, 141.4, 
137.3, 134.1, 129.7, 129.0, 128.6, 126.8, 126.7, 78.2, 59.2, 
38.0, 26.2, 21.0; LRMS m/z (ES) (M+H+) = 315.1; HRMS m/z 
(ES) (M+H+) = 315.1253; HRMS m/z calc. (M+H+) = 
315.1264. 
 
(2R,5S)-5-Benzyl-2,3-dimethyl-2-(4-
cyanophenyl)imidazolidin-4-one 23. Prepared according to 
*HQHUDO 3URFHGXUH >Į@20D   = +41.8 (c 0.1, CH3OH); ȣmax (NaCl 
disk)/cm±1 2228, 1695; 1H NMR (500 MHz, CDCl3 įH 7.57 
(2H, dt, J = 10.4 Hz, 1.7 Hz), 7.31 (2H, dt, J = 10.4 Hz, 1.7 
Hz), 7.24 (2H, t, J = 7. 5 Hz), 7.20±7.15 (3H, m), 3.72 (1H, dd, 
J = 6.3 Hz, 4.7 Hz), 3.07 (1H, dd, J = 14.1 Hz, 4.7 Hz), 3.00 
(1H, dd, J = 14.1 Hz, 6.3 Hz), 2.99 (3H, s), 1.94 (1H, s), 1.45 
(3H, s); 13C NMR (125 MHz, CDCl3 įC 173.6, 147.9, 136.8, 
132.7, 129.6, 128.7, 127.0, 126.1, 118.3, 112.1, 78.2, 59.0, 
37.6, 26.3, 25.8; LRMS m/z (APCI) (M+H+) = 306.2; HRMS 
m/z (ES) (M+H+) = 306.1600; HRMS m/z calc. (M+H+) = 
306.1606. 
 
(2R,5S)-5-Benzyl-2,3-dimethyl-2-(4-
nitrophenyl)imidazolidin-4-one 24. L-Phenylalanine-N-methyl 
amide (3.86 g, 21.7 mmol) was dissolved in DMF (20 mL). 4-
Nitroacetophenone (3.96 g, 24 mmol) was added followed by 
methanesulfonic acid (0.3 mL, 4.63 mmol, 20 mol%). The 
mixture was separated into two microwave vials and subjected 
to microwave irradiation at 150 °C for 30 minutes. The contents 
of the two vials were combined and concentrated under reduced 
pressure. Chloroform (40 mL) and saturated sodium carbonate 
solution (40 mL) were added. The aqueous layer was extracted 
with chloroform (2 × 40 mL) and dried over anhydrous 
potassium carbonate. The solvent was removed under reduced 
pressure and the residue purified by flash chromatography 
(20% ethyl acetate in petroleum ether) to give the title 
FRPSRXQGDVDQRUDQJHRLOPJ>Į@20D   = +24.2 (c=2.0, 
MeOH) ȣmax (ATR)/cm±1 3350, 3028, 2924, 2855, 1688; 1H 
NMR (400 MHz, CDCl3į±8.16 (2H, m), 7.51±7.44 (2H, 
m), 7.36±7.22 (5H, m), 3.83 (1H, app. t, J = 5.3 Hz), 3.18 (1H, 
dd, J = 14.1, 4.6 Hz), 3.11 (1H, dd, J = 14.1, 6.5 Hz), 2.80 (3H, 
s), 2.04 (1H, s), 1.57 (3H, s); 13C NMR (101 MHz, CDCl3 į
173.7, 150.0, 147.8, 136.9, 129.8, 128.8, 127.1, 126.5, 124.2, 
78.2, 59.1, 37.7, 26.4, 26.1; m/z (ES/APCI): 326.2 (M+H+). 
 
General Procedure for imidazolidinone salt formation. A 
solution of the amine in diethyl ether was treated with hydrogen 
chloride gas for 10 minutes. The precipitate was recovered on a 
  
  
sinter, washed with diethyl ether and petroleum ether, then 
dried under reduced pressure.  
 
(S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one 
hydrochloride 13·HCl. mp: 104±106 °C; >Į@20D   = -71.5 (c=1.3, 
MeOH) ȣmax (ATR)/cm±1 3416, 3380, 1710; 1H NMR (400 0+]0H2'į±7.27 (5H, m), 4.67 (1H, dd, J = 10.7, 3.5 
Hz), 3.53 (1H, dd, J = 15.2, 3.5 Hz), 3.09 (1H, dd, J = 15.2, 
10.7 Hz), 2.92 (3H, s), 1.75 (3H, s), 1.60 (3H, s); 13C NMR 
 0+] 0H2' į      
62.3, 37.5, 28.3, 26.9, 24.9; m/z (ES): 219.0 (M-Cl-). 
 
(2R,5S)-5-Benzyl-2-(4-methoxyphenyl)-2,3-
dimethylimidazolidin-4-one hydrochloride 20·HCl. mp 117±
119 °C; >Į@30D   = +36.0 (c 0.1, CH3OH); ȣmax (NaCl disk)/cm±1 
3418, 1715, 1608; 13C NMR (125 MHz, CD32' įC 165.8, 
160.1, 133.4, 127.3, 127.1, 126.3, 125.8, 123.6, 113.1, 78.5, 
55.4, 53.1, 32.4, 23.9, 20.1; LRMS m/z (ES) = 311.2 (M±Cl-); 
HRMS m/z (ES) (M±Cl-) = 311.1753; HRMS m/z calc. (M±Cl-) 
= 311.1760.  
 
(2R,5S)-5-Benzyl-2,3-dimethyl-2-phenylimidazolidin-4-one 
hydrochloride 21·HCl. mp 139± & >Į@30D   = +7.6 (c 0.1, 
CH2Cl2); ȣmax (NaCl disk)/cm±1 3412, 2096, 1644; 1H NMR 
(500 MHz, CD32'įH 7.60±7.55 (3H, m), 7.50±7.46 (2H, m), 
7.41 (2H, d, J = 7.6 Hz), 7.36 (2H, t, J = 7.6 Hz), 7.30 (1H, tt, J 
= 7.60 Hz, 2.4 Hz), 4.44 (1H, dd, J = 9.7 Hz, 4.0 Hz), 3.57 (1H, 
dd, J = 15.2 Hz, 4.0 Hz), 3.24 (1H, dd, J = 15.2 Hz, 9.7 Hz), 
2.94 (3H, s), 2.21 (3H, s); 13C NMR (125 MHz, CD32' įC 
167.6, 134.9, 134.3, 130.8, 129.5, 129.0, 128.8, 127.4, 126.9, 
80.5, 58.6, 34.0, 26.2, 19.4; LRMS m/z (ES) = 281.2 (M±Cl-); 
HRMS m/z (ES) (M±Cl-) = 281.1646; HRMS m/z calc. (M±Cl-) 
= 281.1654. 
 
(2R,5S)-5-Benzyl-2-(4-chlorophenyl)-2,3-
dimethylimidazolidin-4-one hydrochloride 22·HCl. mp 133±
 & >Į@30D   = +38.0 (c 0.1, CH3OH); ȣmax (NaCl disk)/cm±1 
3414, 1720, 1495; 1H NMR (500 MHz, CD32'įH 7.58 (2H, 
dt, J = 8.8 Hz, 1.9 Hz), 7.47 (2H, dt, J = 8.8 Hz, 1.9 Hz), 7.42 
(2H, d, J = 7.4 Hz), 7.36 (2H, t, J = 7.4 Hz), 7.30 (1H, t, J = 7.4 
Hz), 4.46 (1H, dd, J = 9.7 Hz, 4.0 Hz), 3.57 (1H, dd, J = 15.2 
Hz, 4.0 Hz), 3.25 (1H, dd, J = 15.24 Hz, 9.7 Hz), 2.93 (3H, s), 
2.20 (3H, s); 13C NMR (125 MHz, CD32' įC 167.3, 136.8, 
134.9, 132.4, 129.6, 129.0, 128.7, 128.2, 127.3, 79.6, 58.0, 
33.8, 25.5, 22.2; LRMS m/z (APCI) = 315.1 (M±Cl-); HRMS 
m/z (ES) (M±Cl-) = 315.1257; HRMS m/z calc. (M±Cl-) = 
315.1264.  
 
(2R,5S)-5-Benzyl-2,3-dimethyl-2-(4-
cyanophenyl)imidazolidin-4-one hydrochloride 23·HCl. mp 
109± & >Į@26D   = +43.6 (c 0.1, CH3OH); ȣmax (NaCl 
disk)/cm±1 3415, 2534, 2231, 1722; 1H NMR (500 MHz, 
CD32'įH 7.91 (2H, d, J = 8.6 Hz), 7.65 (2H, d, J = 8.6 Hz), 
7.40 (2H, d, J = 7.5 Hz), 7.34 (2H, t, J = 7.5 Hz), 7.28 (1H, t, J 
= 7.5 Hz), 4.44 (1H, dd, J = 9.6 Hz, 3.9 Hz), 3.55 (1H, dd, J = 
15.2 Hz, 3.9 Hz), 3.23 (1H, dd, J = 15.2 Hz, 9.6 Hz), 2.93 (3H, 
s), 2.21 (3H, s); 13C NMR (125 MHz, CD32'įC 167.4, 138.7, 
134.9, 133.2, 129.0, 128.7, 127.7, 127.3, 117.3, 114.5, 79.3, 
58.1, 33.8, 25.6, 22.1; LRMS m/z (APCI) = 306.1 (M±Cl-); 
HRMS m/z (ES) (M±Cl-) = 306.1597; HRMS m/z calc. (M±Cl-) 
= 306.1606;  
 
2R,5S)-5-Benzyl-2,3-dimethyl-2-(4-
nitrophenyl)imidazolidin-4-one hydrochloride 24·HCl. mp 
153±155 °C; >Į@20D   = +36.4 (c=2.0, MeOH); ȣmax (ATR)/cm±1 
1732; 1H NMR (400 MHz, CDCl3į+GJ = 8.8 Hz), 
7.58 (2H, d, J = 8.8 Hz), 7.44±7.27 (5H, m), 4.28 (1H, app. t, J 
= 5.7 Hz), 3.43 (1H, dd, J = 15.1, 5.7 Hz), 3.31 (1H, dd, J = 
15.1, 5.7 Hz), 2.80 (3H, s), 1.82 (3H, s); 13C NMR (101 MHz, 
CDCl3 į       
128.1, 124.6, 79.3, 58.0, 34.6, 26.6, 23.3; m/z (ES/APCI): 326.1 
(M-Cl-). HRMS (ES) calculated for C18H20O3N3 326.1499 
(M+H+), found 326.1498. 
 
General Procedure for Diels Alder cycloaddition (Tables 2 
and 3). Imidazolidinone hydrochloride salt (0.1 mmol, 5 mol%) 
was dissolved in a 19:1 methanol/water mixture (2 mL). The 
flask was placed into a 25 °C oil bath. The appropriate aldehyde 
(2.0 mmol) was added and the mixture was stirred for 10 
minutes before freshly distilled cyclopentadiene (420 µL, 5.0 
mmol) was added in one portion. The reaction mixture was 
stirred for 6 h and then the volatiles were removed under 
reduced pressure. The residue was taken up into chloroform (10 
mL) and water (10 mL) and the aqueous layer was extracted 
with chloroform (2 × 10 mL). The combined organics were 
dried over sodium sulfate and the solvent was removed under 
reduced pressure. Chloroform (2 mL), water (1 mL) and TFA 
(1 mL) were added and the biphasic mixture was vigorously 
stirred for 2 hours. Potassium carbonate (20 mL) was added and 
the mixture was extracted with chloroform (3 × 10 mL). The 
combined organics were dried over sodium sulfate and the 
solvent was removed under reduced pressure. The products 
were isolated using flash chromatography (10% ethyl acetate in 
petroleum ether) as oils. 
 
Monitoring Diels-Alder cycloaddition between 
cinnamaldehyde and cyclopentadiene (Figure 5). Secondary 
amine salt (0.25 mmol, 5 mol%) was dissolved in methanol 
(4.75 mL) and water (0.25 mL). The mixture was stirred at 25 
°C. After 5 minutes, cinnamaldehyde (630 µL, 5 mmol) was 
added. After another 10 minutes, freshly distilled 
cyclopentadiene (1020 µL, 12.5 mmol) was added and the 
reaction timer started. 100 µL aliquots were periodically 
removed and concentrated under reduced pressure (25 °C, 15 
torr, 10 minutes). Water (5 mL) was added and extracted with 
diethyl ether (3 × 5 mL). The combined organics were 
concentrated under reduced pressure. Chloroform (2 mL) was 
added followed by a mixture of TFA/water 1:1 (2 mL). The 
biphasic mixture was vigorously stirred for 2 h. The reaction 
was quenched with saturated sodium carbonate solution (5 mL) 
and extracted with diethyl ether (3 × 5 mL). The combined 
organics were dried over magnesium sulfate and the solvent 
was removed under reduced pressure to give a yellow oil. 1H 
NMR (CDCl3) was used to assess reaction conversion from the 
CHO resonances: exo 9.93 ppm (1H, d, J = 2.0 Hz, CHO), 
cinnamaldehyde 9.71 ppm (1H, d, J = 7.7 Hz, CHO) and endo 
9.60 ppm (1H, d, J = 2.2 Hz, CHO). The Diels-Alder adducts 
can be isolated by flash chromatography (20% ethyl acetate in 
petroleum ether) to give a pale yellow viscous oil. 
 
endo-3-Phenylbicyclo[2.2.1]hept-5-ene-2-carbaldehyde 26 
and exo-3-phenylbicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
27. endo/exo mixture ȣmax (film)/cm±1 3414, 2972, 1717; exo 1H 
NMR (500 MHz, CDCl3į+GJ = 2.0 Hz), 7.41±7.12 
(5H, m), 6.35 (1H, dd, J = 5.5, 3.5 Hz), 6.09 (1H, dd, J = 5.5, 
2.9 Hz), 3.77±3.72 (1H, m), 3.26±3.21 (2H, m), 2.62±2.58 (1H, 
  
  
m), 1.66±1.55 (2H, m); endo 1H NMR (500 MHz, CDCl3 į
9.61 (1H, d, J = 2.2 Hz), 7.38±7.11 (5H, m), 6.43 (1H, dd, J = 
5.6, 3.2 Hz), 6.19 (1H, dd, J = 5.6, 2.8 Hz), 3.35 (1H, br. s), 
3.16±3.09 (1H, m), 3.03±2.96 (1H, m), 1.60±1.55 (2H, m); 
endo/exo mixture 13C NMR (126 MHz, CDCl3į02.8, 
143.6, 142.7, 139.3, 136.6, 136.4, 133.9, 128.7, 128.2, 127.9, 
127.4, 126.4, 126.3, 60.9, 59.5, 48.5, 48.4, 47.6, 47.2, 45.8, 
45.5, 45.5, 45.2; m/z (EI): 198.1 (M+). 
 
endo-3-(4-Methoxyphenyl)bicyclo[2.2.1]hept-5-ene-2-
carbaldehyde and exo-3-(4-
methoxyphenyl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
Table 3 Entry 1. endo/exo mixture ȣmax (film)/cm±1: 2965, 
2934, 2907, 2833, 1712; exo 1H NMR (500 MHz, CDCl3 į
9.92 (1H, d, J = 2.1 Hz, CHO), 7.10±7.06 (2H, m), 6.83±6.79 
(2H, m), 6.35 (1H, dd, J = 5.6, 3.2 Hz), 6.08 (1H, dd, J = 5.6, 
2.9 Hz), 3.78 (3H, s), 3.67 (1H, dd, J = 5.1, 3.7 Hz), 3.22 (1H, 
s), 3.18 (1H, s), 2.56±2.53 (1H, m), 1.64±1.60 (1H, m), 1.58±
1.54 (1H, m); endo 1H NMR (500 MHz, CDCl3į+G
J = 2.3 Hz, CHO), 7.22±7.18 (2H, m), 6.88±6.84 (2H, m), 6.42 
(1H, dd, J = 5.6, 3.2 Hz), 6.17 (1H, dd, J = 5.6, 2.8 Hz), 3.80 
(3H, s), 3.33 (1H, s), 3.08 (1H, s), 3.04 (1H, d, J = 4.5 Hz), 
2.96±2.93 (1H, m), 1.80 (1H, app. d, J = 8.7 Hz), 1.64±1.60 
(1H, m); endo/exo mixture 13C NMR (126 MHz, CDCl3 į
203.8, 203.0, 158.3, 158.1, 139.4, 136.7, 136.4, 135.7, 134.8, 
133.8, 128.9, 128.4, 114.1, 113.7, 61.0, 59.8, 55.4, 55.4, 48.8, 
48.7, 47.7, 47.2, 45.6, 45.2, 45.2, 44.9; due to fragmentation, 
mass spectrometric analysis of the parent aldehydes was not 
possible; m/z of corresponding alcohols (CI): 231.1 (M+H+). 
 
endo-3-(4-Methylphenyl)bicyclo[2.2.1]hept-5-ene-2-
carbaldehyde and exo-3-(4-
methylphenyl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
Table 3 Entry 2. endo/exo mixture ȣmax (film)/cm±1: 2968, 
2941, 2918, 2874, 2912, 2710, 1715; exo: 1H NMR (500 MHz, 
CDCl3į +G J = 2.1 Hz, CHO), 7.09±7.03 (4H, m), 
6.34 (1H, dd, J = 5.7, 3.2 Hz), 6.08 (1H, dd, J = 5.7, 2.9 Hz), 
3.69 (1H, dd, J = 5.2, 3.2 Hz), 3.24±3.19 (2H, m), 2.57 (1H, 
app. dt, J = 5.2, 1.8 Hz), 2.31 (3H, s), 1.64±1.53 (2H, m); endo: 
1H NMR (500 MHz, CDCl3į+GJ = 2.3 Hz), 7.20±
7.11 (4H, m), 6.42 (1H, dd, J = 5.6, 3.2 Hz), 6.17 (1H, dd, J = 
5.6, 2.8 Hz), 3.33 (1H, s), 3.10 (1H, s), 3.05 (1H, d, J = 4.6 Hz), 
2.98±2.95 (1H, m), 2.33 (3H, s), 1.81 (1H, app. d, J = 8.7 Hz), 
1.64±1.53 (1H, m); endo/exo mixture: 13C NMR (126 MHz, 
CDCl3 į   , 139.7, 139.3, 136.7, 136.4, 
136.0, 135.9, 133.9, 129.4, 129.0, 127.9, 127.4, 60.9, 59.6, 
48.7, 48.5, 47.7, 47.2, 45.6, 45.5, 45.2, 21.0; due to 
fragmentation, mass spectrometric analysis of the parent 
aldehydes was not possible; m/z of corresponding alcohol (CI): 
215.1 (M+H+). 
 
endo-3-(4-Chlorophenyl)bicyclo[2.2.1]hept-5-ene-2-
carbaldehyde and exo-3-(4-
Chlorophenyl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
Table 3 Entry 3. endo/exo mixture ȣmax (film)/cm±1: 3061, 
2970, 2872, 2810, 2712, 1715; exo: 1H NMR (500 MHz, 
CDCl3į 9.91 (1H, d, J = 1.8 Hz, CHO), 7.24±7.20 (2H, m), 
7.10±7.06 (2H, m), 6.36 (1H, dd, J = 5.6, 3.2 Hz), 6.06 (1H, dd, 
J = 5.6, 2.9 Hz), 3.71 (1H, dd, J = 5.1, 3.6 Hz), 3.26±3.22 (1H, 
m), 3.19 (1H, br. s), 2.52±2.55 (1H, m), 1.62±1.56 (2H, m); 
endo: 1H NMR (500 MHz, CDCl3į+GJ = 2.1 Hz), 
7.30±7.26 (2H, m), 7.22±7.19 (2H, m), 6.42 (1H, dd, J = 5.7, 
3.2 Hz), 6.18 (1H, dd, J = 5.7, 2.8 Hz), 3.36 (1H, s), 3.12±3.08 
(1H, m), 3.07 (1H, d, J = 4.1 Hz), 2.95±2.90 (1H, m), 1.77 (1H, 
app. d, J = 8.7 Hz), 1.67±1.63 (1H, m); endo/exo mixture: 13C 
NMR (126 MHz, CDCl3 į     
136.6, 136.4, 133.9, 132.2, 132.1, 129.3, 128.8, 128.8, 128.3, 
61.1, 59.7, 48.5, 48.4, 47.7, 47.2, 45.6, 45.2, 45.2, 44.9; m/z 
(EI): 232.0 (M+); HRMS (EI) calculated for C14H13OCl35 
232.0649 (M+), found 232.0652.  
 
endo-3-(4-Nitrophenyl)bicyclo[2.2.1]hept-5-ene-2-
carbaldehyde and exo-3-(4-nitrophenyl)bicyclo[2.2.1]hept-
5-ene-2-carbaldehyde Table 3 Entry 4. endo/exo mixture ȣmax 
(film)/cm±1: 3063, 2972, 2943, 2872, 2818, 2717, 1713, 1514, 
1342; exo: 1H NMR (500 MHz, CDCl3į+GJ = 1.4 
Hz, CHO), 8.07 (2H, d, J = 8.7 Hz), 7.28 (2H, d, J = 8.7 Hz), 
6.39 (1H, dd, J = 5.6, 3.2 Hz), 6.03 (1H, dd, J = 5.6, 2.8 Hz), 
3.88±3.84 (1H, m), 3.28 (1H, s), 3.24 (1H, s), 2.61 (1H, app. d, 
J = 5.1 Hz), 1.59 (2H, br. s); endo: 1H NMR (500 MHz, CDCl3) į+GJ = 1.4 Hz, CHO), 8.13 (2H, d, J = 8.6 Hz), 7.41 
(2H, d, J = 8.6 Hz), 6.42 (1H, dd, J = .6, 3.3 Hz), 6.18 (1H, dd, 
J = 5.6, 3.0 Hz), 3.41 (1H, s), 3.19 (1H, d, J = 4.9 Hz), 3.17 
(1H, s), 2.96±2.93 (1H, m), 1.77±1.66 (2H, m); endo/exo 
mixture: 13C NMR (126 MHz, CDCl3 į   
150.7, 146.6, 146.5, 139.1, 137.1, 136.1, 134.1, 128.8, 128.3, 
123.9, 123.4, 61.2, 59.6, 48.5, 48.0, 47.7, 47.2, 45.7, 45.6, 45.2, 
45.1; due to fragmentation, mass spectrometric analysis of the 
parent aldehydes was not possible; m/z of corresponding 
alcohol (CI): 246.1 (M+H+). 
 
endo-3-Propylbicyclo[2.2.1]hept-5-ene-2-carbaldehyde and 
exo- 3-propylbicyclo[2.2.1]hept-5-ene-2-carbaldehyde Table 
3 Entry 5. Secondary amine salt (0.1 mmol, 1 mol%) was 
dissolved in methanol (9.5 mL) and water (0.5 mL). The 
mixture was stirred at 25 °C. trans-2-Hexenal (1.16 mL, 10 
mmol) was added and the mixture stirred for 10 minutes before 
freshly distilled cyclopentadiene (2.00 mL, 25 mmol) was 
added. After 18 h the solvent was removed under reduced 
pressure (100 mbar, 25 °C). Water (20 mL) and diethyl ether 
(20 mL) were added to the residue and the aqueous layer 
extracted with diethyl ether (2 × 20 mL). The organics were 
dried over sodium sulfate and the solvent removed under 
reduced pressure (100 mbar, 25 °C). Chloroform (4 mL) was 
added to the residue followed by a 1:1 water and TFA mixture 
(4 mL). The biphase was vigorously stirred for 2 hours. The 
reaction was then quenched with saturated sodium carbonate 
solution and the aqueous layer extracted with diethyl ether (3 × 
20 mL). The combined organics were dried over sodium sulfate 
and the solvent removed under reduced pressure (100 mbar, 25 
°C). The product was isolated by flash chromatography (5% 
diethyl ether in petroleum ether) to give a colourless oil. ȣmax 
(ATR)/cm±1: 2957, 2918, 2870, 1717; exo 1H NMR (400 MHz, 
CDCl3į+GJ = 2.7 Hz, CHO, 6.20 (1H, dd, J = 5.6, 
3.1 Hz), 6.13 (1H, dd, J = 5.6, 2.9 Hz), 3.01 (1H, s, J = 1.3 Hz), 
2.87 (1H, s), 2.32±2.24 (1H, m), 1.77±1.73 (1H, m), 1.55±1.04 
(6H, m), 0.90 (3H, t, J = 7.1 Hz); endo 1H NMR (400 MHz, 
CDCl3į6 (1H, d, J = 3.4 Hz), 6.27 (1H, dd, J = 5.7, 3.2 
Hz), 6.05 (1H, dd, J = 5.7, 2.8 Hz), 3.11 (1H, s), 2.66 (1H, d, J 
= 1.5 Hz), 2.37 (1H, dd, J = 7.8, 3.4 Hz), 1.71±1.65 (1H, m), 
1.56±1.03 (6H, m), 0.90 (3H, t, J = 7.1 Hz). endo and exo 
mixture: 13C NMR (101 MHz, CDCl3 į   
136.2, 136.2, 132.9, 60.2, 58.9, 47.4, 47.2, 46.6, 45.2, 42.1, 
38.2, 36.6, 21.8, 21.7, 14.3; m/z (CI): 181 (M++CH5), 163 
(M-H-). 
 
  
  
endo-3-Isopropylbicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
and exo-3-Isopropylbicyclo[2.2.1]hept-5-ene-2-
carbaldehyde Table 3 Entry 6. Secondary amine salt (0.1 
mmol, 1 mol%) was dissolved in methanol (9.5 mL) and water 
(0.5 mL). The mixture was stirred at 25 °C. trans-4-Methyl-2-
hexenal (1.16 mL, 10 mmol) was added and the mixture stirred 
for 10 minutes before freshly distilled cyclopentadiene (2.00 
mL, 25 mmol) was added. After 18 h the solvent was removed 
under reduced pressure (100 mbar, 25 °C). Water (20 mL) and 
diethyl ether (20 mL) were added to the residue and the 
aqueous layer extracted with diethyl ether (2 × 20 mL). The 
organics were dried over sodium sulfate and the solvent 
removed under reduced pressure (100 mbar, 25 °C). 
Chloroform (4 mL) was added to the residue followed by a 1:1 
water and TFA mixture (4 mL). The biphase was vigorously 
stirred for 2 hours. The reaction was then quenched with 
saturated sodium carbonate solution and the aqueous layer 
extracted with diethyl ether (3 × 20 mL). The combined 
organics were dried over sodium sulfate and the solvent 
removed under reduced pressure (100 mbar, 25 °C). The 
product was isolated by flash chromatography (5% diethyl ether 
in petroleum ether) to give a colourless oil. ȣmax (ATR)/cm±
1:2957, 2911, 2895, 2870, 1701; exo 1H NMR (400 MHz, 
CDCl3į+GJ = 2.6 Hz, CHO), 6.19 (1H, dd, J = 5.6, 
3.1 Hz), 6.15 (1H, dd, J = 5.6, 2.8 Hz), 3.04±3.00 (1H, m), 2.96 
(1H, s), 1.92±1.84 (2H, m), 1.51±1.40 (2H, m), 1.08±0.97 (1H, 
m), 0.94 (3H, d, J = 6.2 Hz), 0.84 (3H, d, J = 6.4 Hz); endo 1H 
NMR (400 MHz, CDCl3į36 (1H, d, J = 3.4 Hz, CHO), 6.26 
(1H, dd, J = 5.7, 3.3 Hz), 6.06 (1H, dd, J = 5.7, 2.8 Hz), 3.11 
(1H, s, CH), 2.87±2.83 (1H, m), 2.51±2.47 (1H, m), 1.51±1.39 
(1H, m), 1.34±1.29 (1H, m), 1.01 (1H, d, J = 6.5 Hz), 0.91 (1H, 
d, J = 6.6 Hz); endo/exo mixture 13C NMR (101 MHz, CDCl3) į         
50.2, 47.0, 46.6, 45.3, 45.3, 45.1, 45.1, 32.9, 32.6, 22.1, 22.1, 
21.9, 21.6; m/z (CI): 181 (M++CH5), 163 (M-H-). 
 
General procedure for monitoring reaction between 
cinnamaldehyde and N-methyl pyrrole 
 
(S)-3-(1-Methyl-1H-pyrrol-2-yl)-3-phenylpropan-1-ol. 
Secondary amine salt (10 mol%, 0.21 mmol) was dissolved in 
THF (4 mL) and water (0.6 mL). The mixture was stirred at 25 
°C and after 5 minutes cinnamaldehyde (250 µL, 2 mmol) was 
added. Stirring was continued for 10 minutes before N-methyl 
pyrrole (530 µL, 5.97 mmol) was added in one portion. 
Aliquats (100 µL) were periodically taken and added to a 
mixture of sodium borohydride (5 mg, 0.13 mmol) in ethanol (1 
mL). After 15 minutes the reduction was quenched with 
saturated sodium bicarbonate solution (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The organics were dried 
over sodium sulfate and the solvent removed under reduced 
pressure. The residue was analysed by 1H NMR to determine 
reaction conversion using resonances: 4.33 ppm (2H, dd, 
CH2OH) from cinnamyl alcohol and 4.15 (1H, t, PhCH) from 
the product. The product was isolated using flash 
chromatography (16% ethyl acetate in petroleum ether) as a 
colourless oil. ȣmax (ATR)/cm±1 3246, 2965, 2930, 2864; 1H 
NMR (500 MHz, CDCl3į±7.28 (2H, m, CH), 7.24±7.17 
(3H, m, CH), 6.58±6.54 (1H, m, CH), 6.20±6.14 (2H, m, CH), 
4.15 (1H, app. t, J = 7.6 Hz, PhCH), 3.74±3.57 (2H, m, 
CH2OH), 3.32 (3H, s, NCH3), 2.42±2.31 (1H, m, CHH), 2.17±
2.07 (1H, m, CHH), 1.78 (1H, s, OH); 13C NMR (126 MHz, 
CDCl3 į       
105.8, 60.6, 39.5, 39.0, 33.9; m/z (ES): 216.0 (M+H+). 
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